At Symeres, we recognize that the transition from research to development is a critical stage in the drug discovery and development process. Unforeseen issues in chemistry, manufacturing, and controls (CMC) can cause costly delays, so early identification and mitigation of risk are essential.
Our teams apply decades of experience to evaluate and strengthen synthetic routes before they move into clinical supply. We provide:
- Route scouting to identify the most efficient and scalable synthetic pathways.
- Risk assessments to flag potential challenges in yield, purity, or scalability.
- Catalyst screening to optimize selectivity, efficiency, and sustainability.
- Early safety studies to ensure that hazardous intermediates or conditions are recognized and controlled.
These activities are supported by parallel experimentation and design-of-experiment (DoE) approaches, allowing us to explore variables systematically and select robust, reliable, and scalable routes.
Over the past 30 years, Symeres has successfully developed hundreds of novel routes for innovative APIs. Our track record ensures that when clients partner with us, they can move forward with confidence, knowing their clinical supply is underpinned by sound chemistry and proactive risk management.
Discover Exemplify
We deliver a number of services in partnership with Exemplify BioPharma, a global Partnership Research Organization (PRO) offering end-to-end CMC solutions under one roof.
Exemplify offers:
- Integrated project management across Process Chemistry, Analytical Chemistry, and Formulation Development
- Expert oversight on CRO/CMO selection, contracting, and management
- Comprehensive support with CMC regulatory submissions (IND, IMPD, NDA, MAA)
- Full Quality Assurance and compliance sign-off
- Efficient timeline and budget management
Their newly expanded Formulation Suite also opens the door to enhanced formulation capabilities, strengthening support from early development through to commercialization.
